前列地尔注射液与缬沙坦联合治疗早期糖尿病肾病的临床疗效分析  

Clinical efficacy analysis of alprostadil injection combined with valsartan in the treatment of early diabetic nephropathy

作　　者：邵小飞 SHAO Xiao-fei(Third Affiliated Hospital of Southern Medical University,Guangzhou 510000,China)

机构地区：[1]南方医科大学第三附属医院,510000

出　　处：《中国实用医药》2022年第22期35-38,共4页China Practical Medicine

摘　　要：目的分析早期糖尿病肾病患者应用前列地尔注射液联合缬沙坦治疗的效果。方法86例早期糖尿病肾病患者,采用随机数字表法分为观察组和对照组,每组43例。两组患者均进行饮食管理,在此基础上,对照组应用缬沙坦治疗,观察组应用前列地尔注射液与缬沙坦联合治疗。比较两组患者治疗前后血糖[空腹血糖(FBG)、餐后2 h血糖(2 h PG)]、血压[收缩压(SBP)和舒张压(DBP)]、肾功能指标[血尿素氮(BUN)、血肌酐(Scr)以及尿白蛋白排泄率(UAER)]水平以及临床疗效、药物不良反应(头晕、皮疹、心动过速、胃肠道反应)发生情况。结果治疗后,观察组患者FBG(6.13±0.22)mmol/L、2 h PG(7.32±0.35)mmol/L、SBP(126.35±5.01)mm Hg(1 mm Hg=0.133 kPa)、DBP(72.63±3.06)mm Hg均低于对照组的(6.50±0.25)mmol/L、(7.69±0.58)mmol/L、(129.69±6.17)mm Hg、(76.35±4.05)mm Hg,差异均具有统计学意义(P<0.05)。治疗后,观察组患者BUN(4.20±0.22)mmol/L、Scr(71.16±11.56)μmol/L、UAER(86.35±14.63)μg/min均低于对照组的(5.26±0.59)mmol/L、(80.36±11.86)μmol/L、(116.35±31.16)μg/min,差异均具有统计学意义(P<0.05)。观察组治疗总有效率97.67%高于对照组的86.05%,差异具有统计学意义(P<0.05)。观察组药物不良反应发生率4.65%与对照组的6.98%比较,差异无统计学意义(P>0.05)。结论对早期糖尿病肾病患者应用前列地尔注射液联合缬沙坦治疗的效果显著,且有助于改善肾功能及调控血糖、血压水平,且安全性良好。Objective To analyze the effect of alprostadil injection combined with valsartan in the treatment of early diabetic nephropathy.Methods A total of 86 patients with early diabetic nephropathy were divided into observation group and control group by random numerical table,with 43 cases in each group.Both groups received diet management.On this basis,the control group was treated with valsartan,and the observation group was treated with combined treatment of alprostadil injection and valsartan.The blood glucose[fasting blood glucose(FBG),2-h postprandial glucose(2 h PG)],blood pressure[systolic blood pressure(SBP)and diastolic blood pressure(DBP)],renal function indexes[blood urea nitrogen(BUN),serum creatinine(Scr)and urinary albumin excretion rate(UAER)]levels,clinical efficacy,and occurrence of adverse drug reactions(dizziness,rash,tachycardia,gastrointestinal reactions).Results After treatment,the FBG(6.13±0.22)mmol/L,2 h PG(7.32±0.35)mmol/L,SBP(126.35±5.01)mm Hg(1 mm Hg=0.133 kPa),DBP(72.63±3.06)mm Hg in the observation group were lower than(6.50±0.25)mmol/L,(7.69±0.58)mmol/L,(129.69±6.17)mm Hg,(76.35±4.05)mm Hg in the control group,and the differences were all statistically significant(P<0.05).After treatment,the BUN(4.20±0.22)mmol/L,Scr(71.16±11.56)μmol/L and UAER(86.35±14.63)μg/min of the observation group were all lower than(5.26±0.59)mmol/L,(80.36±11.8)μmol/L,(116.35±31.16)μg/min of the control group,and the differences were all statistically significant(P<0.05).The total effective rate 97.67%of the observation group was higher than 86.05%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse drug reactions in the observation group was 4.65%,and the difference was not statistically significant compared with 6.98%in the control group(P>0.05).Conclusion Alprostadil injection combined with valsartan is significantly effective for patients with early diabetic nephropathy,and can help to improve the renal function and regulate blood glucose and b

关 键 词：糖尿病肾病 前列地尔注射液 缬沙坦 肾功能 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]